Biologic relevance of lipoxygenase isoforms in atherogenesis

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 6, 2005, Pages 1099-1110

  Kuhn, Hartmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Eicosanoids; Gene expression; Inflammation; Leukotrienes; Oxidative stress

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; GLUTATHIONE PEROXIDASE; ICOSANOID; INTERLEUKIN 4; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; SCAVENGER;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROGENESIS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL MATURATION; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; DEGENERATIVE DISEASE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MOLECULAR MODEL; MONOCYTE; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYLOGENY; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; ISOENZYMES; LIPOXYGENASE; MODELS, BIOLOGICAL;

EID: 28644452197     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.3.6.1099     Document Type: Review

References (83)

1. Lusis AJ. Atherosclerosis. Nature 407, 233-241 (2000).
2. Libby P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
3. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Hypothesis of oxidative modification. N. Engl. J. Med. 320, 915-924 (1989).
5. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic. Biol. Med. 28, 1815-1826 (2000).
6. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 274, 23679-23682 (1999).
7. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294, 1871-1875 (2001).
8. Rapoport SM, Schewe T, Thiele BJ. Maturational breakdown of mitochondria and other organelles in reticulocytes. In: Blood Cell Biochemistry 1. Harris, JR (Ed.). Plenum Press, NY, 151-194 (1990).
9. van Leyen K, Duvoisin RM, Engelhardt H, Wiedmann M. A function for lipoxygenase in programmed organelle degradation. Nature 395, 392-395 (1998).
10. Pidgeon GP, Kandouz M, Meram A, Honn KV. Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res. 62, 2721-2727 (2002).
11. Klein RF, Allard J, Avnur Z et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 303, 229-332 (2004).
12. Shankaranarayanan P, Nigam S. IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15-hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor gamma transcription factor. J. Immunol. 170, 887-894 (2003).
13. Sparrow CP, Parthasarathy S, Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J. Lipid Res. 29, 745-753 (1988).
14. Belkner J, Wiesner R, Rathman J, Barnett, J, Sigal E, Kühn H. Oxygenation of lipoproteins by mammalian lipoxygenases. Eur. J. Biochem. 213, 251-261 (1993).
15. Shen J, Herderick, E, Cornhill F et al. Macrophage-mediated 15-lipoxygernase expression protects against atherosclerosis development. J. Clin. Invest. 98, 2201-2208 (1996).
16. Trebus F, Heydeck D, Schimke L, Gerth C, Kühn H. Transient experimental anemia in cholesterol-fed rabbits induces systemic overexpression of the reticulocyte-type 15-lipoxygenase and protects from aortic lipid deposition. Prostaglandins Leukot. Essent. Fatty Acids 67, 419-428 (2002).
17. Munger KA, Montero A, Fukunaga M et al. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. USA 96, 13375-13380 (1999).
18. Serhan CN, Jain A, Marleau S et al. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171, 5856-6865 (2003).
19. Gillmor SA, Villasenor A, Fletterick R, Sigal E, Browner MF. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nature Structural Biol. 4, 1003-1009 (1997).
20. Noguchi N, Yamashita H, Hamahara J, Nakamura A, Kuhn H, Niki E. The specificity of lipoxygenase-catalyzed lipid peroxidation and the effects of radical-scavenging antioxidants. Biol. Chem. 383, 619-626 (2002).
21. Kuhn H, Thiele B. The diversity of lipoxygenase family. FEBS Lett. 449, 7-11 (2000).
22. Funk CD, Chen XS, Johnson EN, Zhao L. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat. 68-69, 303-312 (2002).
23. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237, 1171-1176 (1987).
24. Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am. J. Respir. Crit. Care Med. 157, 233-237 (1998).
25. Janssen-Timmen U, Vickers PJ, Wittig U et al. Expression of 5-lipoxygenase in differentiating human skin keratinocytes. Proc. Natl. Acad. Sci. USA 92, 6966-6970 (1995).
26. Luo M, Pang CW, Gerken AE, Brock TG. Multiple nuclear localization sequences allow modulation of 5-lipoxygenase nuclear import. Traffic 5, 847-854 (2004).
27. Chaitidis P, O'Donnell V, Kuban RJ, Bermudez-Fajardo A, Ungethuem U, Kuhn H. Gene expression alterations of human peripheral blood monocytes induced by medium-term treatment with the TH2-cytokines interleukin-4 and -13. Cytokine 30, 366-437 (2005).
28. Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc. Natl Acad. Sci. USA 71, 3400-3404 (1974).
29. Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fatty Acids 69(2-3), 99-109 (2003).
30. Martel-Pelletier J, Mineau F et al. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor β and eicosanoids. Arthritis Rheum. 50, 3925-3393 (2004).
31. Nadel JA, Conrad DJ, Ueki IF, Schuster A, Sigal E. Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. J. Clin. Invest. 87, 1139-1145 (1991).
32. Yla-Herttuala S. Macrophages and oxidized low density lipoproteins in the pathogenesis of atherosclerosis. Ann. Med. 23, 561-567 (1991).
33. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S et al. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J. Clin. Invest. 87, 1146-1152 (1991).
34. Spanbroek R, Grabner R, Lotzer K et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA 100, 1238-1243 (2003).
35. Conrad DJ, Kuhn H, Mulkins M, Highland E, Sigal E, Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc. Natl Acad. Sci. USA 89, 1217-2221 (1992).
36. Xu B, Bhattacharjee A, Roy B et al. Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3. Mol. Cell. Biol. 23, 3918-3928 (2003).
37. Schewe T, Rapoport SM, Kuhn H. Enzymology and physiology of reticulocyte lipoxygenase: comparison with other lipoxygenases. Adv. Enzymol. Relat. Areas Mol. Biol. 58, 191-272 (1986).
38. Ostareck DH, Ostareck-Lederer A, Shatsky IN, Hentze MW. Lipoxygenase mRNA silencing in erythroid differentiation: the 3′UTR regulatory complex controls 60S ribosomal subunit joining. Cell 104, 281-290 (2001).
39. Brinckmann R, Schnurr K, Heydeck D, Rosenbach T, Kolde G, Kuhn H. Membrane translocation of 15-lipoxygenase in hematopoietic cells is calcium-dependent and activates the oxygenase activity of the enzyme. Blood 91, 64-74 (1998).
40. Chang WC. Cell signaling and gene regulation of human 12(S)-lipoxygenase expression. Prostaglandins Other Lipid Mediat. 71, 277-285 (2003).
41. Hung JJ, Wang YT, Chang, WC. Deacetylation of SP1 induceed by phorbol ester recruits P300 to activate 12-lipoxygenase transcription in A431 cells. Proceedings of the International Eicosanoid Conference on Basic Science & Clinical Application. Beijing, China (2005).
42. Kühn H, Heydeck, D, Brinckman R, Trebus F. Regulation of cellular 15-lipoxygenase activity on pre-translational, translational and post-translational levels. Lipids 34, S273-279 (1999).
43. Chang WC. Identification of an endogenous inhibitor of arachidonate metabolism in human epidermoid carcinoma A431 cells. J. Biomed. Sci. 10, 599-606 (2003)
44. Berger M, Schwarz K, Thiele H et al. Simultaneous expression of leukocyte-type 12-lipoxygenase and reticulocyte-type 15-lipoxygenase in rabbits. J. Mol. Biol. 278, 935-948 (1998).
45. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc. Natl Acad. Sci. USA 94, 6148-6152 (1997).
46. Krieg P, Kinzig A, Heidt M, Marks F, Furstenberger G. cDNA cloning of a 8-lipoxygenase and a novel epidermis-type lipoxygenase from phorbol ester-treated mouse skin. Biochim. Biophys. Acta 1391, 7-12 (1998).
47. Sun D, Funk C. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. J. Biol. Chem. 271, 24055-24062 (1996).
48. Sendobry SM, Cornicelli JA, Welch K, Grusby MJ, Daugherty A. Absence of T lymphocyte-derived cytokines fails to diminish macrophage 12/15-lipoxygenase expression in vivo. J. Immunol. 161, 1477-1482 (1998).
49. Heydeck D, Thomas L, Schnurr et al. Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood. 92, 2503-2510 (1998).
50. Levy BD, Romano M, Chapman HA, Reilly JJ, Drazen J, Serhan CN. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 92, 1572-1579 (1993).
51. Steinberg D. Putting inflammation and hypercholesterolemia in perspective in the pathogenesis of atherosclerosis. Mol. Nutr. Food Res. (2005) (In Press).
52. Nakao J, Ito H, Koshihara Y, Chang WC, Murota S. Mode of action of aortic smooth-muscle cell migration induced by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid and platelet-derived growth factor. Adv. Prostaglandin Thromboxane Leukot. Res. 15, 681-683(1985).
53. Henriksson P, Hamberg M, Diczfalusy U. Formation of 15-HETE as a major hydroxyeicosatetraenoic acid in the atherosclerotic vessel wall. Biochim. Biophys. Acta 834, 272-274 (1985).
54. Goodman DS, The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs. Drugs 33 (Suppl. 1), 47-55 (1987).
55. Mehrabian M, Allayee H, Wong J et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 91, 120-126 (2002).
56. Zhao L, Moos MP, Grabner R. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Med. 10, 966-973 (2004).
57. Kuhn H, Anton M, Gerth C, Habenicht A. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis-resistant mice confer impaired activity when introduced into the human ortholog. Arterioscler. Thromb. Vasc. Biol. 23, 1072-1076 (2003).
58. Dwyer JH, Allayee H, Dwyer KM et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350, 29-37 (2004).
59. Kuhn H, Belkner J, Suzuki H, Yamamoto S. Oxidative modification of human lipoproteins by lipoxygenases of different positional specificities. J. Lipid Res. 35, 1749-1759 (1994).
60. Nagano Y, Arai H, Kita T, High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc. Natl Acad. Sci. USA 88, 6457-6461 (1991).
61. Benz DJ, Mol M, Ezaki M et al. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblast expressing high levels of human 15-lipoxygenase. J. Biol. Chem. 270, 5191-5197 (1995).
62. Xu W, Takahashi Y, Sakashita T, Iwasaki T, Hattori H, Yoshimoto T. Low density lipoprotein receptor-related protein is required for macrophage-mediated oxidation of low density lipoprotein by 12/15-lipoxygenase. J. Biol. Chem. 276, 36454-36459 (2001).
63. Sparrow CP, Olszewski J. Cellular oxidative modification of low density lipoprotein does not require lipoxygenases. Proc. Natl Acad. Sci. USA 89, 128-131 (1992).
64. Kuhn H, Römisch I, Belkner J. The role of lipoxygenase-isoforms in atherogenesis. Mol. Nutr. Food Res. (2005) (In Press).
65. Ylä-Herttuala S, Luoma J, Viita H, Hiltunen T, Nikkari T. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid protein adducts characteristic of oxidized low density lipoprotein. J. Clin. Invest. 95, 2692-2698 (1995).
66. Harats D, Shaish A, George J et al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20, 2100-2105 (2000).
67. Cyrus T, Pratico D, Zhao L et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 103, 2277-2282 (2001).
68. George J, Afek A, Shaish A et al. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104, 1646-1650 (2001).
69. Huo Y, Zhao L, Hyman MC et al. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation 110, 2024-2031 (2004).
70. Sendobry SM, Cornicelli JA, Welch K et al. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br. J. Pharmacol. 20, 1199-1206 (1997).
71. Kühn H, Belkner J, Zaiss S, Fährenklemper T, Wohlfeil S. Involvement of 15-lipoxygenase in early stages of atherogenesis. J. Exp. Med. 179, 1903-1911 (1994).
72. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J. Clin. Invest. 96, 504-150 (1995).
73. Kuhn H, Heydeck D, Hugou I, Gniwotta C. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J. Clin. Invest. 99, 888-893 (1997).
74. Cornicelli JA. 15-lipoxygenase inhibitors as anti-atherosclerotic agents. Curr. Res. Vasc. Dis. 3, 163-170 (1998).
75. Zhang L, Chawla A. Role of PPARγ in macrophage biology and atherosclerosis. Trends Endocrinol. Metab. 15, 500-505 (2004).
76. Coffey MJ, Jarvis GE, Gibbins JM et al. Platelet 12-lipoxygenase activation via glycoprotein VI: involvement of multiple signaling pathways in agonist control of H(P)ETE synthesis. Circ. Res. 94, 1598-1605 (2004).
77. Belkner J, Chaitidis P, Stender H et al. Expression of 12/15-lipoxygenase attenuates intracellular lipid deposition during in vitro foam cell formation. Arterioscler. Thromb. Vasc. Biol. 25, 797-802 (2005).
78. Kühn H. Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)xy-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)xy-9Z, 11E-octadecadienoic acid. Prog. Lipid Res. 35, 203-226 (1996).
79. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat. 68-69, 433-455 (2002).
80. Cathcart MK, Folcik VA. Lipoxygenases and atherosclerosis: protection versus pathogenesis. Free Radic. Biol. Med. 28, 1726-1734 (2000).
81. Kuhn H, Chan L. The role of 15-lipoxygenase in atherogenesis: pro- and antiatherogenic actions. Curr. Opin. Lipidol. 8, 111-117 (1997).
82. Conrad DJ. The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function. Clin. Rev. Allergy Immunol. 17, 71-89 (1999).
83. Richards KM, Moody JS, Marnett LJ. Mechanism of inhibition of porcine leukocyte 12-lipoxygenase by the isoform-specific inhibitor 4-(2-oxapentadeca-4-yne)phenylpropanoic acid. Biochemistry 38, 16529-16538 (1999).